First FDA Approval for a Treatment Directly Targeting Demodex Mites

A panel of eye care experts—including an ophthalmic surgeon, ophthalmologist, optometrist (OD), payer, and ophthalmic assistant—discuss lotilaner ophthalmic solution 0.25%, the first treatment for Demodex blepharitis approved by the US Food and Drug Administration.

The panel consisted of:

• Marjan Farid, MD, of Gavin Herbert Eye Institute and the University of California, Irvine
• Eric D. Donnenfeld, MD, of Ophthalmic Consultants of Long Island Vision
• Paul Karpecki, OD, of Kentucky Eye Institute
• Jeffrey Dunn, PharmD, MBA, of Cooperative Benefits Group
• Derrick Sterling, COA, OSC, of KTND Ophthalmology Associates

Learn how this therapy works, from the science behind it to real-world evidence supporting its use in this patient population.